Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Climb Bio, Inc. - Common Stock (NQ:CLYM)

6.380 -0.360 (-5.34%)
Streaming Delayed Price Updated: 11:23 AM EDT, Apr 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Climb Bio, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Global Phase 2 open-label clinical trial in pMN (PrisMN) enrolling, with initial data anticipated H2 2026 
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to be Added to the Nasdaq Biotechnology Index
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
News headline image
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
From Climb Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.